Recent clinical trials have illuminated the potential of combination therapies in treating advanced cancers, showcasing innovative approaches that yield promising efficacy and manageable safety profiles across various cancer types. A phase II trial highlighted the effectiveness of sintilimab, a PD-1 targeting antibody, combined with albumin-bound paclitaxel in treating recurrent or metastatic cervical cancer, achieving an objective response rate of 44.4%, a disease control rate of 88.9%, and median survival times of 5.2 months for progression-free survival and 13.1 months for overall survival, despite a notable incidence of grade 3 or 4 adverse events. Similarly, the SCORPION trial in Japan assessed the combination of docetaxel plus ramucirumab as a second-line therapy for non-small cell lung cancer (NSCLC) patients, reporting an objective response rate of 34.4% with no treatment-related deaths, suggesting its viability as a second-line option. Adding to this body of evidence, a single-arm, open-label phase 1 trial investigated the combination of pyrotinib, an irreversible pan-HER inhibitor, with camrelizumab, an anti-PD-1 antibody, and chemotherapy as a first-line treatment for HER2-positive advanced gastric and gastroesophageal junction adenocarcinoma. Enrolling 41 patients between June 2020 and June 2022, the study identified a maximum tolerated dose of pyrotinib at 320 mg daily and reported a confirmed objective response rate of 77.8% at the recommended phase 2 dose, underlining the potential of this innovative approach in offering a new treatment avenue for patients with this challenging cancer type. Together, these studies underscore the significant advancements in the therapeutic landscape of advanced cancers, highlighting the need for further research through larger randomized controlled trials to validate these findings and potentially expand treatment options.